Table 3.
Recommendations of TURBT and re-TURBTa
| Guideline ID | TURBT | Re-TURBT | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Be recommended | Adequate resection with muscle in specimen | No muscle in original specimen | Ta | T1 | Interval between TURBT and Re-TURBT | ||||||
| SOR/LOE | G&S | SOR/LOE | G&S | SOR/LOE | G&RS | SOR/LOE | G | SOR/LOE | Interval | SOR/LOE | |
| ESMO, 2014 [8] | −/− | – | A/I | – | −/− | High-risk | B/II-III | – | B/II-III | – | −/− |
| NICE, 2015 [9]b | −/− | – | A/low-very low | – | A/low-very low | High-risk | A/low-very low | – | A/low-very low | 6 | A/low-very low |
| CUA, 2015 [10] | −/− | – | A/− | Only T1 | A/− | HG | C/− | – | C/− | 2–6 | A/− |
| AUA/SUO, 2016 [3] | −/− | – | −/− | – | Strong/B | High-risk, HG | Moderate/C | – | Strong/B | 6 | −/− |
| JUA, 2016 [11] | A/− | – | −/− | – | −/− | – | −/− | HG | A/− | – | −/− |
| EAU, 2018 [12] | Strong/1b | Except for TaG1/LG | Strong/1b | Except for TaG1/LG and primary CIS | Strong/1b-3 | – | −/− | – | Strong/1b-3 | 2–6 | Weak/3 |
| ICUD/SIU, 2018 [13] | C/3 | – | −/− | – | B/2 | HG | C/3 | – | B/2 | 6 | B-C/2–3 |
| CRHA/CPAM, 2018 [14] | A/4 | Except for TaG1/LG | A/4 | – | A/4 | G3/HG | A/4 | – | A/4 | 6 | A/4 |
| NCCN, 2019 [15]c | −/− | Except for TaLG | B/2A | Only HG | B/2A | > 3 cm or multi-focal | B/2A | – | B/2A | 6 | B/2A |
G Grading, S Staging, RS Risk stratification, HG High grade, CIS Carcinoma in situ
a The SOR and LOE are presented as “SOR/LOE”. “-” indicates that the recommendation or evidence was not presented
b To simplify the table, we used “A” and “B” instead of “should/should not/offer/do not offer/refer/advise” or “consider” for presenting SOR
c To simplify the table, we used “A” and “B”, “C” instead of “preferred intervention”, “other recommended intervention”, or “useful in certain circumstances” for presenting SOR